Russia's Sputnik-V Applies for Pre-qualification from WHO

A glad tiding has been reported in Russia, where RDIF has solicited WHO with the view of getting Sputnik-V registered and pre-qualified. Sputnik-V is a Russia based vaccine to treat corona-virus patients. According to sources, 85% of patients show no side effects of the potential vaccine.

RDIF ( Russian Direct Investment Fund) said in its statement that the Russian Federation is one of the first to apply for accelerated registration under EUL (Emergency Use Listing) and pre qualification for Sputnik-V. According to its statement, quickened antibody enlistment under the EUL method will make the Russian immunization accessible worldwide in a more limited time span than regular techniques and will uphold worldwide endeavors to forestall the Covid contamination. It was set up in 2011.

WHO is responsible for the United Nations' pre-qualification of medicines program. It is the main worldwide drug quality confirmation program. The WHO prequalification of prescriptions evaluates the quality, security, and viability of medications.

Kirill Dmitriev, CEO of RDIF, expressed his gratitude towards the World Health Organisation who actively cooperated and he looks forward to the pre-qualification process without any complications. He also said that Sputnik-V is designed safely, effectively, and is perfectly suitable for human use.

The Sputnik V antibody is the world's initially enrolled immunization against Coronavirus dependent on the human adenoviral vector stage. It is right now going through stage 3 clinical preliminary in Russia, with the engineers wanting to select 40,000 members. Stage 3 preliminary for the immunization was likewise begun in the UAE a week ago.

Related News:

• COVID-19 vaccine progress: know how close we are to the corona vaccine
• A 14-year-old girl discovers a vaccine that can cure Covid-19
• COVID 19 Vaccine: States starts preparation to create Health Workers Database (HWD)

The fortunate pre-qualification will avail the countries and other international bodies for early and mass procurement of vaccines. It was developed by Gamaleya Research Institute and was launched on 11 August 2020 by Russian Health Ministry. India's trial on Sputnik-V is expected to end by March 2021. Dr. Reddy's together with RDIF received assent from DCGI (Drug Control General of India) to conduct further clinical trials on Russia's covid vaccine.